Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03818802 · ClinicalTrials.gov registry record · NA

Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging

A NA study of Healthy Elderly Volunteers, sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
53
Enrollment target
1
Study location

NCT03818802: Completed NA study of Healthy Elderly Volunteers, sponsored by Mayo Clinic.

NCT03818802 is a NA study of Healthy Elderly Volunteers that has completed, run by Mayo Clinic. The registered enrollment target is 53 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03818802, a NA study of Healthy Elderly Volunteers, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
53 participants
Enrollment target
1
Study location

Study Summary

Researchers are trying to determine if the vitamin B3 derivative Nicotinamide Riboside (NR) has any effects in bone, skeletal muscle, and metabolic functions and structure in aging.

Primary Outcome

Maximal oxygen uptake (VO2 max) test measures the maximum rate of oxygen consumption during incremental exercise (exercise of increasing intensity) and reflects the cardiorespiratory fitness of an individual and is an important determinant of their endurance capacity during prolonged exercise.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Nicotinamide Riboside

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2019-09-16
Est. Completion 2024-11-08
Phase NA
Mayo Clinic

2,844 total trials

What the finished NCT03818802 record still lists

NCT03818802 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Healthy Elderly Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03818802 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT03818802 about?

NCT03818802 is a clinical study titled "Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging". Researchers are trying to determine if the vitamin B3 derivative Nicotinamide Riboside (NR) has any effects in bone, skeletal muscle, and metabolic functions and structure in aging.

What is the current status of trial NCT03818802?

This trial is currently completed. It is a NA study. The enrollment target is 53 participants. The study started on 2019-09-16. Estimated completion is 2024-11-08.

What conditions does trial NCT03818802 study?

This clinical trial studies the following conditions: Healthy Elderly Volunteers.

What interventions are being tested in trial NCT03818802?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Nicotinamide Riboside (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03818802?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03818802 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT03818802's enrollment target sits among peer trials

53 1271st of 2000 higher than 729 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04177004 · 53 participants · Phase 1

    Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

  • NCT04199741 · 53 participants · Phase 1

    PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

  • NCT04835129 · 53 participants · Phase 2

    Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

  • NCT04913805 · 53 participants · Phase 2

    Matching Perfusion and Metabolic Activity in HFpEF

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03818802, the US trial registry maintained by the National Library of Medicine. NCT03818802 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.